Evidence map›Paper›PMID 29180070›Full record

ArticleAnalytical biochemistry2018

A high-throughput screening campaign to identify inhibitors of DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD).

Amanda Haymond, Tyrone Dowdy, Chinchu Johny, Claire Johnson, Haley Ball, Allyson Dailey, Brandon Schweibenz, Karen Villarroel, Richard Young, Clark J Mantooth and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Amanda HaymondDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Tyrone DowdyDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Chinchu JohnyDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Claire JohnsonDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Haley BallDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Allyson DaileyDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Brandon SchweibenzDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Karen VillarroelDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Richard YoungDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Clark J MantoothDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Trishal PatelDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Jessica BasesDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA.
Cynthia S DowdDepartment of Chemistry, George Washington University, Washington DC 20052, USA. Electronic address: cdowd@gwu.edu.
Robin D CouchDepartment of Chemistry and Biochemistry, George Mason University, Manassas, VA 20110, USA. Electronic address: rcouch@gmu.edu.

Funding

Inhibition of MEP pathway Isoprenoid BiosynthesisR01AI123433 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI DOWD, CYNTHIA SCHIECK, MEYERS, MARVIN J · 2016 to 2020
$2.6M
NIAID NIH HHS R01 AI123433
6 · The paper itself

Abstract

The rise of antibacterial resistance among human pathogens represents a problem that could change the landscape of healthcare unless new antibiotics are developed. The methyl erythritol phosphate (MEP) pathway represents an attractive series of targets for novel antibiotic design, considering each enzyme of the pathway is both essential and has no human homologs. Here we describe a pilot scale high-throughput screening (HTS) campaign against the first and second committed steps in the pathway, catalyzed by DXP reductoisomerase (IspC) and MEP cytidylyltransferase (IspD), using compounds present in the commercially available LOPAC

Indexed as

High-Throughput Screening AssaysAldose-Ketose IsomerasesAnti-Bacterial AgentsEnzyme InhibitorsMolecular StructureMycobacterium tuberculosisNucleotidyltransferasesRecombinant ProteinsYersinia pestis1-deoxy-D-xylulose 5-phosphate reductoisomerase2-C-methyl erythritol 4-phosphate cytidylyltransferaseAldose-Ketose IsomerasesAnti-Bacterial AgentsEnzyme InhibitorsNucleotidyltransferasesRecombinant ProteinsAntimicrobial developmentHTS assay developmentLOPAC(1280)MEP pathway

Identifiers

PMID29180070
PMCPMC5817008

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.